Tilray, Inc. was incorporated in 2018 in Canada and researches, cultivates, processes, and distributes medical cannabis. Tilray is a global company and sells its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa.
Tilray was the first Canadian-based marijuana stock to go public on a US exchange (Nasdaq), was one of the first medical cannabis companies in Canada to be issued a cultivation license and will be one of the main recipients to benefit when Canada open its recreational-marijuana market in October.
One year ago today, Tilray was more valuable than 50% of the companies on the S&P 500. Because the float at the time was only 10 MM, people wanted in and drove the price of the stock to $300/share. But because people came to their senses and because 20% of the float was short the stock, Tilray is down 90%, which could spell an opportunity longer term.
As I’m sure you’ve heard, the vaping crisis has captured the nation’s attention. Increasingly, the public, including some vape users, are leery about the practice.
And that sentiment suits TLRY stock for the long haul. Tilray’s products are consumables wrapped in unassuming and discreet labeling. Designed purely for medicinal purposes, they don’t have the stigma associated with stereotypical cannabis platforms.
Plus, the vaping crisis provides an opportunity for TLRY to distinguish itself as a medicinal player, not a recreational one. That’s crucial as it reaches out to the international markets.
In a surprising report from CNBC, many Asian countries are turning toward medical cannabis. Historically known for their draconian narcotics laws, if Asia converts to green, it would be a game-changer, irrespective of what happens in the U.S.
For example, Japan recently approved clinical trials for Epidiolex, a cannabidiol (CBD)-based oral solution for helping epileptic patients. Consequently, Japan also has a rapidly aging population. If medical cannabis gains greater acceptance there, it would represent a huge boon for specialists like Tilray. Logically, this would skyrocket Tilray stock, perhaps back to its intra-day highs.
So where is Tilray headed short term, if price can close above $35 on the daily chart, the chart suggests to look for a short term target at $43.
This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.